An Clinical Study of Evecare Forte Liquid in PCOS (Polycystic Ovarian Syndrome)

Phase 2

• Conditions: Health Condition 1: E282- Polycystic ovarian syndrome

• Registration Number: CTRI/2017/12/011004
• Lead Sponsor: The Himalaya Drug Company

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 24 November 2021

Recruitment & Eligibility

• Status: ot Yet Recruiting
• Sex: Not specified
• Target Recruitment: 0

Inclusion Criteria

1. Women with signs and symptoms of PCOS like irregular menstrual cycles, weight gain, biochemical/clinical hyperandrogenemia, hirsutism etc.

2. History of PCOS with < 8 periods the preceding year.

3. PCOS confirmed by Clinical and/or biochemical and/or ultrasonographical findings.

4. Willingness to sign consent for study including participation with collection of blood specimens.

Exclusion Criteria

1. Patients who is not using oral contraceptive pills, hormonal treatment or IUCDs.

2. Patients who had no systemic illness like hypertension, renal disease, tuberculosis, hepatic disease, diabetes, coagulation disorder, etc.

3. Patients with organic lesion of the reproductive tract especially any benign or malignant growth, extensive cervical erosion, cervical polyps, endometriosis.

4. Patients with severe Hepatic/ cardiac/ mental illness.

5. Patients unwilling to provide informed consent or abide by the requirements of the study.

Study & Design

• Study Type: Interventional
• Study Design: Not specified